Literature DB >> 12539153

Marked enhancement in gene expression by targeting the human insulin receptor.

Yun Zhang1, Ruben J Boado, William M Pardridge.   

Abstract

BACKGROUND: Exogenous genes can be delivered to cells without viral vectors using an "artificial virus" comprised of nonviral plasmid DNA encapsulated in the interior of 85 nm pegylated immunoliposomes (PIL). The liposomes are targeted to cells with receptor-specific targeting ligands such as receptor-specific peptidomimetic monoclonal antibodies.
METHODS: The levels of luciferase gene expression in human or rat glioma cells are measured after targeting the PIL-encapsulated plasmid DNA via the human insulin receptor, the human epidermal growth factor receptor, or the rat transferrin receptor. The luciferase expression plasmids were either derived from pCEP4, which contains the Epstein-Barr nuclear antigen-1/oriP replication system, or from pGL2, which lacks this system for episomal replication of plasmid DNA.
RESULTS: Depending on the plasmid construct used and the receptor targeted, the peak luciferase gene expression varied more than 200-fold from 1.8 +/- 0.1 to 419 +/- 31 pg luciferase per mg cell protein. With the same plasmid, the peak level of gene expression following delivery to the cell via the human insulin receptor was 100-200-fold higher than gene expression following delivery via either the epidermal growth factor receptor or the transferrin receptor. There was no gene expression if the targeting ligand on the PIL was replaced with a nonspecific isotype control antibody.
CONCLUSIONS: The extent to which an exogenous gene is expressed within a cell via a nonviral, receptor-mediated gene transfer technology is determined by the receptor specificity of the targeting ligand. The highest levels of gene expression are obtained after targeting the insulin receptor, and this may derive from the nuclear targeting properties of this receptor system. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12539153     DOI: 10.1002/jgm.333

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  13 in total

Review 1.  New technologies for drug delivery across the blood brain barrier.

Authors:  A V Kabanov; E V Batrakova
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

2.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

3.  Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma.

Authors:  Fernanda I Staquicini; Michael G Ozawa; Catherine A Moya; Wouter H P Driessen; E Magda Barbu; Hiroyuki Nishimori; Suren Soghomonyan; Leo G Flores; Xiaowen Liang; Vincenzo Paolillo; Mian M Alauddin; James P Basilion; Frank B Furnari; Oliver Bogler; Frederick F Lang; Kenneth D Aldape; Gregory N Fuller; Magnus Höök; Juri G Gelovani; Richard L Sidman; Webster K Cavenee; Renata Pasqualini; Wadih Arap
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 4.  RNA interference and nonviral targeted gene therapy of experimental brain cancer.

Authors:  Ruben J Boado
Journal:  NeuroRx       Date:  2005-01

Review 5.  Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

6.  Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation.

Authors:  Chun Chu; Yun Zhang; Ruben J Boado; William M Pardridge
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

7.  Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy.

Authors:  Xiao-Hong Ou; An-Ren Kuang; Xian Peng; Yu-Guo Zhong
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

8.  Receptor binding characteristics and cytotoxicity of insulin-methotrexate.

Authors:  Xiao-Hong Ou; An-Ren Kuang; Zheng-Lu Liang; Xian Peng; Yu-Guo Zhong
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

Review 9.  Blood-brain barrier transport of non-viral gene and RNAi therapeutics.

Authors:  Ruben J Boado
Journal:  Pharm Res       Date:  2007-06-08       Impact factor: 4.200

10.  Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer.

Authors:  Yun Zhang; Yuntao Wang; Ruben J Boado; William M Pardridge
Journal:  Pharm Res       Date:  2007-06-30       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.